AR006514A1 - Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende - Google Patents

Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende

Info

Publication number
AR006514A1
AR006514A1 ARP960103427A AR10342796A AR006514A1 AR 006514 A1 AR006514 A1 AR 006514A1 AR P960103427 A ARP960103427 A AR P960103427A AR 10342796 A AR10342796 A AR 10342796A AR 006514 A1 AR006514 A1 AR 006514A1
Authority
AR
Argentina
Prior art keywords
macrolide
producing
pharmaceutical composition
produce
inclusive
Prior art date
Application number
ARP960103427A
Other languages
English (en)
Spanish (es)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513596.8A external-priority patent/GB9513596D0/en
Priority claimed from GBGB9515495.1A external-priority patent/GB9515495D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of AR006514A1 publication Critical patent/AR006514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP960103427A 1995-07-04 1996-07-03 Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende AR006514A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513596.8A GB9513596D0 (en) 1995-07-04 1995-07-04 Organic compounds
GBGB9515495.1A GB9515495D0 (en) 1995-07-28 1995-07-28 Organic compounds

Publications (1)

Publication Number Publication Date
AR006514A1 true AR006514A1 (es) 1999-09-08

Family

ID=26307320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103427A AR006514A1 (es) 1995-07-04 1996-07-03 Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende

Country Status (17)

Country Link
EP (1) EP0836616A1 (cs)
JP (1) JPH11509092A (cs)
KR (1) KR19990028724A (cs)
CN (1) CN1193979A (cs)
AR (1) AR006514A1 (cs)
AU (1) AU708004B2 (cs)
BR (1) BR9609324A (cs)
CA (1) CA2224715A1 (cs)
CO (1) CO4750713A1 (cs)
CZ (1) CZ424297A3 (cs)
HU (1) HUP9802320A3 (cs)
IL (1) IL122844A0 (cs)
NO (1) NO980016L (cs)
PL (1) PL324346A1 (cs)
SK (1) SK498A3 (cs)
TR (1) TR199800001T1 (cs)
WO (1) WO1997002285A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CN101242842A (zh) 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN101289440B (zh) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 一种多烯大环类化合物及其制备方法与应用
ES2556211T3 (es) * 2008-09-24 2016-01-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Agrupación de genes novedosa
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
EP2654753B1 (en) * 2010-12-20 2018-10-31 Neurovive Pharmaceutical AB Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CA2875692A1 (en) * 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
PL2859009T3 (pl) * 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
CA3043131A1 (en) 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements

Also Published As

Publication number Publication date
WO1997002285A1 (en) 1997-01-23
EP0836616A1 (en) 1998-04-22
AU6519396A (en) 1997-02-05
HUP9802320A2 (hu) 1999-02-01
IL122844A0 (en) 1998-08-16
HUP9802320A3 (en) 1999-03-29
MX9800217A (es) 1998-07-31
KR19990028724A (ko) 1999-04-15
JPH11509092A (ja) 1999-08-17
CN1193979A (zh) 1998-09-23
TR199800001T1 (xx) 1998-04-21
NO980016L (no) 1998-03-02
BR9609324A (pt) 1999-05-25
PL324346A1 (en) 1998-05-25
SK498A3 (en) 1998-07-08
AU708004B2 (en) 1999-07-29
NO980016D0 (no) 1998-01-02
CO4750713A1 (es) 1999-03-31
CZ424297A3 (cs) 1998-04-15
CA2224715A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
AR006514A1 (es) Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
KR100203556B1 (ko) 신규의 사이클로스포린
DE68909139D1 (de) Substanz FR901228 und deren Herstellung.
ES2093658T3 (es) Polipeptido ciclico con actividad antibiotica, procedimiento para su preparacion y cultivo puro de una cepa de coelomycetes.
ES2075115T3 (es) Nuevo compuesto polipeptidico y un procedimiento para la preparacion del mismo.
KR890000518A (ko) 시클릭 펩톨라이드
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
BR9810002A (pt) Preparação de <244>1-at nativa purificada cromatograficamente, processo para a preparação da mesma, e, utilização de um material de suporte
EA200100347A1 (ru) Метод и композиция для лечения и профилактики туберкулеза
Fusetani et al. Nazumamide A, a thrombin-inhibitory Tetrapeptide, from a marine sponge, theonella sp.
ES2097736T3 (es) Peptido ciclico con actividad antagonista de sustancia p y sustancia k.
NO960372L (no) Gener som koder for forgrenet alfa-ketosyredehydrogenasekompleks fra Streptomyces avermitilis
ES2084599T3 (es) Metodo para purificar antitrombina iii y preparacion de antitrombina iii que contiene dicha antitrombina iii.
AR004165A1 (es) Una sal de diclavulanato de bis-(2-dialquilaminoalquil)-eter; un procedimiento para preparar la misma; y una composicion farmaceutica que la contiene
GB8802229D0 (en) Ws-9326 & its derivatives
DK0387712T3 (da) WS7622A-, B-, C- og D-stoffer, derivater deraf og fremgangsmåder til fremstilling deraf samt anvendelse deraf
PT98134A (pt) Processo para a preparacao de mono- ou dissulfato do produto (ws7622a) obtido da cultura de uma estirpe de streptomyces resbtomycificus n 0. 7622 e de composicoes farmaceuticas que os contem
AU7386094A (en) T-lymphocyte-containing pharmaceutical composition for treating infections
BR9910763A (pt) Proteìna não-estrutural 4 (nsp4) de rotavìrus composição antigênica, processos para proteger um hospedeiro mamìfero contra doença causada por rotavìrus, e para melhorar sintomas diarréicos em um hospedeiro mamìfero, sequência de ácido nucleico isolada e purificada, plasmìdeo contendo uma sequência de ácido nucleico isolada e purificada, célula hospedeira, e, processo para produzir uma forma alternativa de nsp4 de rotavìrus
JPH0338280B2 (cs)
KR920018226A (ko) 생리활성 캉글레마이신 c, 그 제조방법 및 용도
GB8928811D0 (en) An activator for damaged neurocytes for the prevention and treatment of disease